Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, which will be retained by Cidara Cidara to receive upfront payment of $30 million and equity investment of $9 million, co-development funding, development milestones and tiered royalty stream Total transaction value could exceed $568 million Cidara to…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak® antiviral program have been accepted for presentation at the Options X for the Control of Influenza conference taking place August 28-September 1 in Singapore. "Cidara's presentations at this important global conference highlight our commitment to addressing an unmet medical need for better and more effective approaches…

SAN DIEGO, Aug. 08, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate activities and product pipeline. "We have made important advances in both our rezafungin program to treat and prevent fungal disease as well as our Cloudbreak® immunotherapy program for the treatment and prevention of influenza," said Jeffrey Stein,…

SAN DIEGO, Aug. 07, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019, at 10:20 a.m. EDT (7:20 a.m. PDT) in New York City. A live audio webcast and replay of the presentation will be available in the Investors section…

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Global Phase 3 ReSTORE trial ongoing Company to host conference call today at 8:00 a.m. ET/5:00 a.m. PT SAN DIEGO, July 29, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported positive topline results from Part B of the global…

Company secures two oral and four poster presentations Presentations include new data highlighting the antiviral effect and immune system engagement of CB-012 for the prevention and treatment of flu SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data from studies of rezafungin, the company's Phase 3 antifungal, and CB-012, its Cloudbreak® antiviral Fc-conjugate (AVC) candidate for influenza, will be presented at the American…

SAN DIEGO, May 09, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended March 31, 2019 and provided an update on its corporate activities and product pipeline. "Cidara made significant progress to begin 2019 by continuing to enroll patients in and advance our global Phase 3 ReSTORE trial of rezafungin for the treatment of patients with candidemia and invasive candidiasis,"…

Data featured in three oral and five poster presentations reinforce potential of novel antifungal for the treatment and prevention of serious invasive infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, highlighted new data from multiple studies of rezafungin, the company's lead investigational compound, this week during the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Amsterdam, Netherlands. Rezafungin is the only once-weekly product…

CB-012 demonstrates potent antiviral activity against influenza A and B viruses Cidara presenting preclinical results today at ECCMID 2019 SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the company has selected the antiviral conjugate (AVC) CB-012 as its first clinical development candidate from the company's Cloudbreak® influenza (antiviral) program. Data supporting the selection will be presented today in an oral session at the 29th…

SAN DIEGO, April 03, 2019 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019, at 11:20 a.m. EDT (8:20 a.m. PDT) in New York City. A live audio webcast and replay of the presentation will be available in the Investors section…